Eagle Pharmaceuticals (EGRX) Posts Mixed Q1 Results

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of ($0.36), $0.10 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5 million versus the consensus estimate of $3.2 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Bristow Group to acquire Berry Aviation for $105 million
• Davidson Hospitality Group Appoints Joe Masi as Senior Vice President, Operations